RIVASTIGMINE GenPar PATCH 15 rivastigmine 13.3 mg/24 hours transdermal drug delivery system sachet

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

rivastigmine, Quantity: 27 mg

Available from:

Arrotex Pharmaceuticals Pty Ltd

INN (International Name):

Rivastigmine

Pharmaceutical form:

Drug delivery system, transdermal

Composition:

Excipient Ingredients: acrylates copolymer; ethyl acetate; hexane; 2-ethylhexyl acrylate; methyl acrylate; acrylic acid; acrylates/ethylhexyl acrylate copolymer; methylated trimethylated silica

Administration route:

Transdermal

Units in package:

7 sachets, 30 sachets

Prescription type:

(S4) Prescription Only Medicine

Therapeutic indications:

RIVASTIGMINE GENPAR PATCH is indicated for the treatment of patients with mild, moderate and severe dementia of the Alzheimer?s type.

Product summary:

Visual Identification: Circular 15cm2 transdermal patch, tri-layer adhesive matrix, translucent white backing film labelled with "Rivastigmine 13.3 mg/24 h"; Container Type: Sachet; Container Material: Other composite material; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius

Authorization status:

Licence status A

Authorization date:

2017-01-25